

**DESIGN, OPTIMIZATION AND EVALUATION OF PEG-COATED
MEMANTINE LOADED PLGA NANOSCAFFOLDS FOR
MANAGEMENT OF ALZHEIMER'S DISEASE**



**Thesis submitted in partial fulfillment for the
Award of Degree**

Doctor of Philosophy

By

Varsha Rani

**DEPARTMENT OF PHARMACEUTICAL ENGINEERING AND TECHNOLOGY
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI- 221005
INDIA**

Roll No. 17161005

Year 2023

CERTIFICATE

It is certified that the work contained in the thesis titled "Design, Optimization and Evaluation of PEG-coated Memantine Loaded PLGA Nanoscaffolds for Management of Alzheimer's Disease" by Varsha Rani has been carried out under my supervision and this work has not been submitted elsewhere for a degree. It is further certified that the student has fulfilled all the requirements of Comprehensive Examination, Candidacy and SOTA.

Pravda
19.9.23

Signature of Supervisor

Dr. Ruchi Chawla

Associate Professor

Department of Pharmaceutical

Engineering and Technology

Indian Institute of Technology

(Banaras Hindu University)

Varanasi - 221005

Uttar Pradesh

Dr. (Mrs.) Ruchi Chawla
Associate Professor
Department of Pharmaceutical
Engineering & Technology
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI-221005

DECLARATION BY THE CANDIDATE

I, Varsha Rani, certify that the work embodied in this thesis is my own bona fide work and carried out by me under the supervision of Dr. Ruchi Chawla, Associate Professor from 26 July 2017 to April 2023, at the Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi. The matter embodied in this thesis has not been submitted for the award of any other degree/diploma. I declare that I have faithfully acknowledged and given credits to the research workers wherever their works have been cited in my work in this thesis. I further declare that I have not willfully copied any other's work, paragraphs, text, data, results, etc., reported in journals, books, magazines, reports dissertations, theses, etc., or available at websites and have not included them in this thesis and have not cited as my own work.

Date: 19.09.2023

Place: Varanasi, India

Varsha Rani
Signature of the Student

CERTIFICATE BY THE SUPERVISOR

It is certified that the above statement made by the student is correct to the best of my/our knowledge.

Ruchi Chawla
17.9.23
Signature of the Supervisor

Dr. Ruchi Chawla

Associate Professor

Department of Pharmaceutical

Engineering and Technology

Indian Institute of Technology

(Banaras Hindu University)

Varanasi – 221005

Uttar Pradesh

S. Hemalatha 19/9/23
Signature of Head of Department
विभागाध्यक्ष / Head

भैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग /
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय) / (BANARAS HINDU UNIVERSITY)
वाराणसी

Dr. (Mrs.) Ruchi Chawla
Associate Professor
Department of Pharmaceutical
Engineering & Technology
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI-221005

COPYRIGHT TRANSFER CERTIFICATE

Title of the Thesis: Design, Optimization and Evaluation of PEG-coated Memantine Loaded PLGA Nanoscaffolds for Management of Alzheimer's Disease

Name of the Student: Varsha Rani

COPYRIGHT TRANSFER

The undersigned hereby assigns to the Indian Institute of Technology (Banaras Hindu University), Varanasi all rights under copyright that may exist in and for the above thesis submitted for the award of the Doctor of Philosophy (Ph.D.) in Pharmaceutics.

Date: 19.09.2023

Varsha Rani
Signature of the Student

Place: Varanasi, India

Note: However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for author's personal use provided that the source and the Institute's copyright notice are indicated

ACKNOWLEDGEMENT

*It gives me immense pleasure to be a part of Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh. First and foremost, I want to thank my supervisor **Dr. Ruchi Chawla**, Associate Professor, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University). It has been an honor to be her Ph.D. student. She provided me a platform on which my career will grow and flourish. Throughout the tenure, she provided encouragement, advice, good teaching, and lots of good ideas. I appreciate all her contributions of time, ideas and suggestions to make my Ph.D. experience productive and stimulating. I would like to express my special appreciation and gratitude to Research Progress Evaluation Committee (RPEC) members: Dr. Ruchi Chawla, Prof. B. Mishra; and Dr. Abha Mishra. Each of the members of my RPEC committee has provided me extensive personal and professional guidance and taught me a great lesson about impactful scientific research. Also, express my sincere thanks to all my teachers Dr. Sairam Krishnamurthy, Dr. Sushant Kumar Shrivastava, Dr. Sushil Kumar Singh, Dr. Alakh Niranjana Sahu, Dr. Gyan Prakash Modi, Dr. M. S. Muthu, Dr. Senthil Raja A, Dr. Sunil Kumar Mishra, Dr. Vinod Tiwari, Dr. Ashish Kumar Agrawal, Dr. Prasanta Kumar Nayak, Dr. Shreyans Kumar Jain, Dr. Dinesh Kumar, Dr. Rajnish, Dr. Deepak Kumar, Dr. Jairam Meena and Dr. Arun Khattri of Department of Pharmaceutical Engineering and Technology for their support, helpful lessons, encouragement, and discussions.*

My sincere thanks to Prof. Pramod Kumar Jain (Director), Prof. Shyam Bihari Dwivedi (Dean of Academic Affairs) and Prof. Lal Pratap Singh (Dean of Student's Affairs) and Prof. S. Hemalatha (HOD, Department of Pharmaceutical Engineering and Technology), for providing healthy work atmosphere with the best of facilities and intellectually inspiring environment. I am thankful to Institute of Medical Science (IMS), DBT-BHU Interdisciplinary School of Life Sciences (ISLS), Banaras Hindu University, Central Instrument Facility, IIT (BHU) and Instrument Facility of Department of Pharmaceutical Engineering and Technology for providing advanced research equipment facility for conducting my research work. I am also thankful to finance section of Indian Institute of Technology (Banaras Hindu University) for providing my fellowship and Research support grant. I also give my sincere thanks to Dr. Vinod Tiwari, who provided his expert guidance for conducting in-vivo experimentation taking due care of Animal ethical guidelines. My thanks also go to all the staff members of Department of Pharmaceutical Engineering and Technology for providing me with instrumental facilities. I am extremely thankful to Mr. Virendra Kumar, Smt. Archana Singh, Mr. Arun Kumar, Mr. Mohd. Jameel, Mr. Akhila Nand Upadhyay, Mr. Nand Lal, Mr. Chhote Lal, Mr. Ram Hriday Pathak and Km. Shyamali Ghosal for their invaluable technical inputs and non-technical staff Mr. Atul Kumar Gupta, Mr. Yashwant Singh, Dr. Anand Kumar, Mr. Surya Pratap Singh for their friendly behaviour and ever ready help during my

research project. I want to thank my labmates and friends Ms. Rinki Verma, Ms. Sangeeta Hazarika, Ms. Mohini Mishra, Mr. Tarkeshwar Dubey, Mr. Krishan Kumar Mr. Atul Jadhav and Ms. Deeksha Sonkar for healthy ideas and discussion about my research work and making friendly environment in research lab.

I owe thanks to a very special person of my life, my husband, Dr. Sanjay Kumar for his continued and unfailing love, support and understanding during my pursuit of Ph. D. degree that made the completion of thesis possible. He has always been a major source of support when things would get a bit discouraging. This journey would not have been possible without the support of my parents, brothers and sisters. Thank you for giving me strength to reach for the stars and chase my dreams. I am especially grateful to my father, who supported me emotionally and financially. I always knew that you believed in me and wanted the best for me. Thank you for teaching me the right things in my life, to be happy and confident, and to keep faith in myself for living a worthwhile life at the same time contributing to the wellbeing of other in the society.

Varsha Rani

Contents

	List of abbreviations	i
	List of Figures.....	iii
	List of Tables.....	v
1	Introduction.....	3
1.1	Alzheimer’s Disease (AD).....	5
1.2	Diagnostics for AD: labelling and imaging.....	5
1.3	Pathogenesis of AD	5
1.3.1	Amyloid β and AD pathogenesis	6
1.3.2	Hyperphosphorylation of τ and Microglial infiltration leading to neurodegeneration.....	7
1.4	Nanotechnology as a therapeutic tool for drug delivery across the BBB	9
1.5	Therapeutics in AD.....	10
1.5.1	Modulating neurotransmission	10
1.5.2	Cholinesterase system.....	10
1.5.3	N-methyl D-aspartate antagonism	13
1.5.4	Amyloid Targeted strategies.....	14
1.5.5	Modulating A β transport.....	15
1.5.6	Decreasing A β aggregation by passive immunization therapy.....	16
1.6	Memantine for the treatment of moderate to severe Alzheimer’s	17
1.7	Self-Assembled Nanoscaffolds.....	17
2	Literature Review	21
2.1	Literature Review related to Memantine	21
2.2	Literature review on the development of memantine-loaded nanocarriers.	22
2.3	Literature Review: Self-assembled nanocarriers	24
2.4	Mechanism of action of self-assembled PLGA nanoscaffolds.....	26
2.5	Selection of Intrathecal route over oral route of administration.....	27
3	Drug and Excipient Profile	31
3.1	Memantine	31
3.1.1	Dosage and Administration	31
3.1.2	Mechanism of action of Memantine	31
3.1.3	Pharmacokinetics	32

3.2	PLGA.....	33
3.3	Pluronic F-127.....	34
3.4	Polyethylene Glycol (PEG)	35
3.5	Bone Marrow stem cell (BMSCs)	37
4	Aim and objective	41
4.1	Aim	41
4.2	Objectives	41
5	Materials and Methods	45
5.1	Preparation of nanoscaffolds	45
5.2	Methods for determination of response variables.....	45
5.2.1	Optimization of nanoscaffolds.....	45
5.2.2	Determination of Drug Loading (%)	46
5.3	Characterization of Optimised Memantine loaded Nanoscaffolds	46
5.3.1	Surface morphology (SEM).....	46
5.3.2	Entrapment Efficiency and Drug Loading.....	47
5.3.3	Biodegradability study.....	47
5.3.4	Preparation of Pegylated Memantine loaded self-assembled PLGA Nanoscaffolds (PEG-MEM-PLGA) SANS.....	47
5.3.5	Characterization of (PEG-MEM-PLGA) SANS	49
5.4	<i>In-vitro</i> studies	51
5.4.1	Drug Release study and Kinetic model	51
5.4.2	Blood-brain barrier permeation assay (PAMPA-BBB).....	52
5.5	<i>Ex-vivo</i> Study.....	53
5.5.1	Animal experiments.....	53
5.5.2	Enzyme Kinetic study against Acetylcholinesterase (AChE), Butyrylcholinesterase (BUCHE and β -Secretase in Cortex and Hippocampus	53
5.5.3	Hemocompatibility study	54
5.6	Stem cell grafting.....	55
5.6.1	Neurobehavioral studies	56
5.6.2	Scopolamine induced amnesia model and treatment groups.....	56
5.6.3	Y-Maze Test	56
5.6.4	Morris Water Maze Test.....	57
5.7	Estimation of pro-inflammatory cytokines.....	58
5.7.1	Animal model and treatment groups	58

5.8	Pharmacokinetic and Biodistribution study.....	60
5.8.1	Animal Experiments	60
5.8.2	High Performance Liquid Chromatography analysis of the pharmacokinetic and Biodistribution study	61
5.9	Pharmacodynamic study	62
5.10	Biochemical parameters.....	63
5.11	Histological analysis	63
5.12	Statistical analysis.....	63
6	Results and Discussion.....	67
6.1	Experimental design	67
6.1.1	Statistical analysis of experiments	70
6.1.2	Effect on Porosity (%) and Drug loading	70
6.1.3	Prediction of optimized formulation.....	71
6.1.4	Analysis of Variance.....	72
6.1.5	Response Surface methodology.....	73
6.2	Characterization of Memantine loaded nanoscaffolds.....	78
6.2.1	Surface morphology (SEM).....	78
6.2.2	Percentage porosity	80
6.2.3	Entrapment Efficiency and Drug Loading.....	80
6.2.4	Biodegradation study	81
6.2.5	Swelling index and water uptake study	81
6.3	Characterization of (PEG-MEM-PLGA) SANs	82
6.3.1	Drug and polymer incompatibility study (FTIR) and Thermal Characteristics (TGA and DSC)	82
6.3.2	Surface morphology (SEM, Particle size and Zeta potential)	84
6.3.3	Determination of porosity (%).....	87
6.3.4	Entrapment Efficiency	87
6.3.5	Biodegradation and Swelling index study	87
6.3.6	Stability Studies	89
6.3.7	<i>In-vitro</i> studies	89
6.3.8	<i>Ex-vivo</i> study.....	93
6.3.9	Hemocompatibility study.....	99
6.3.10	Neurobehavioral Effects	100
6.4	Pharmacokinetic and Biodistribution study.....	109
6.4.1	HPLC Study.....	109

6.5	Histological study	121
6.5.1	Histological studies.....	121
6.6	Estimation of pro-inflammatory cytokines.....	123
6.6.1	Expression of pro-inflammatory cytokines in serum, cerebral, hepatic and renal tissues.....	125
6.6.2	Involvement of cytokines in AD	128
6.6.3	Therapeutic effect of Memantine and nanoscaffolds on inflammation in AD	129
6.6.4	Statistical Analysis	134
7	Summary	137
8	Conclusion	147
9	References.....	153
10	Appendix.....	183

(3,3',5,5'-Tetramethylbenzidine)	TMB	24
5,5'-dithio-bis-[2-nitrobenzoic acid]	DTNB	24
7-methoxycoumarin- 4-yl acetyl	MCA.....	33
Amyloid precursor protein	APP	32
Amyloid β -peptide	A β	32
Biotin Conjugated Detection Antibody	BIO-CONJ	24
BoneMarrow-Derived Stem Cell	BMSc.....	34
Drug Loading	DL	26
Foetal Bovine Serum	FBS	34
Human Bone Marrow-Derived Stem Cell	HBMSc	24
MCA-EVKMDAEFK-(DNP)-NH ₂	synthetic APP derivatives	33
Memantine (pure drug)	MEMp	36
Memantine loaded PLGA nanoscaffolds	(MEM-PLGA) SANs	27
Memantine pure drug	MEMp	37
Minimum Essential Media	MEM	34
non-solvent-induced phase separation	N-TIPS	24
Parallel artificial membrane permeation assay	PAMPA- BBB.....	31
PEG coated memantine loaded PLGA self-assembled nanoscaffolds grafted with BoneMarrow-Derived Stem Cell	(PEG-MEM-PLGA) SANs-BMSc.....	34
Pegylated Memantine loaded self-assembled PLGA Nanoscaffolds	PEG-MEM-PLGA) SANs	27
poly (lactic-co-glycolic acid)	PLGA	24
Porcine brain lipid	PBL	24
Scanning electron microscope	SEM.....	26
Streptavidin Horseradish Peroxidase	STRP-HRP	24

List of Figures

Figure 1: Mechanism of neuronal damage and Alzheimer's disease (AD) progression.....	8
Figure 2: Hypothesis of developing Alzheimer's Disease.	9
Figure 3: Structure of Memantine.	31
Figure 4: Glutamnergic pathway and mechanism of action of Memantine.	32
Figure 5: Structure of PLGA where x is number of units of lactic acid; y is number of units of glycolic acid.....	34
Figure 6: Structure of Pluronic F-127 (PEO-PPO-PEO).	34
Figure 7: Structure of Polyethylene glycol where x denotes the average number of oxyethylene groups.	36
Figure 8: Metabolism, degradation and Excretion of PEG and PEG-coated nanocarriers [187]	37
Figure 9: Neurogenesis mediated via stem cells to the site of neurodegeneration.....	38
Figure 10: Preparation of (MEM-PLGA) SANs and (PEG-MEM-PLGA) SANs.	48
Figure 11: Blood-brain barrier permeation assay of MEMp, (MEM-PLGA) SANs and (PEG-MEM-PLGA) SANs.	52
Figure 12: Preparation of (PEG-MEM-PLGA) SANs-BMSc under Biosafety cabinets.	56
Figure 13: Overview of Enzyme linked immunosorbent assay (ELISA) and quantitative estimation of Biomarkers including pro-inflammatory cytokines.....	59
Figure 14: Main effect plot for (a) % drug loading with fitted means of PLGA, Pluronic F127 and Rotation speed (b) % porosity with fitted means of PLGA, Pluronic F127 and Rotation speed.	69
Figure 15: Interaction plot for (a) % drug loading with fitted means of PLGA, Pluronic F127 and Rotation speed (b) % porosity with fitted means of PLGA, Pluronic and Rotation speed.	70
Figure 16: Contour plot of (a) % Drug loading (Y_1) vs PLGA(X_1) and Pluronic F127(X_2) at rotation speed 1000 rpm as holding value (b) % Drug loading (Y_1) vs PLGA(X_1) and Rotation speed (X_3) at Pluronic F127 3%w/v as holding value (c) % Drug loading (Y_1) vs PLGA(X_1) and Pluronic F127(X_2) at rotation speed 1000 rpm as holding value.	73
Figure 17: Contour plot of (a) % Porosity (Y_2) vs PLGA(X_1) and Pluronic F127(X_2) at rotation speed 1000 rpm as holding value (b) % Porosity (Y_2) vs Rotation speed and PLGA (X_1) at Pluronic F127(X_2) 3%w/v as holding value (c) Contour plot of Porosity (Y_2) vs Pluronic F127(X_2) and rotation speed 1000 rpm by keeping 12.5% w/v PLGA(X_1) as holding value..	74
Figure 18: Surface plot of % Drug Loading (Y_1) (a) vs PLGA (X_1) vs Pluronic F127 (X_2) at constant Rotation speed (X_3) of 1000rpm taken as holding value (b) PLGA (X_1) vs Rotation speed (X_3) at 3% w/v Pluronic F127 (X_2) (taken as holding value) (c) Pluronic F127 (X_2) vs Rotation speed (X_3) at 12.5% w/v PLGA (X_1) taken as holding value.	75
Figure 19: Surface plot % Porosity (Y_2) (a) PLGA(X_1) vs Pluronic F127 (X_2) at 1000 rpm Rotation speed (X_3) taken as holding value (b) Pluronic F127 (X_2) vs Rotation speed (X_3) at 12.5% w/v PLGA (X_1) taken as holding value (c) PLGA (X_1) and Rotation speed (X_3) at 3% w/v Pluronic-F127 (X_2) taken as holding value.	76
Figure 20: Optimization response at PLGA concentration (19.18% w/v), Pluronic concentration (4.98% w/v), and Rotation speed(500rpm) which predicted % drug loading at 11.66, and % porosity of 82.62 with a composite desirability (d) 0.88240 and 0.75548 respectively.....	78
Figure 21: SEM of Memantine-loaded nanoscaffolds at scale (a) 200 nm (b) 100 nm.	79
Figure 22: Swelling index of Memantine loaded PLGA nanoscaffolds.....	82
Figure 23. (a) FTIR spectrum of PLGA 50:50/75:25, Pluronic F127, PEG and (PEG-MEM-PLGA) SANs; (b-c) Thermogram (TGA/DTG) of PLGA 50:50/75:25, PEG, Pluronic F127 and (PEG-MEM-PLGA) SANs from temperature 30 °C to 600 °C.	84

Figure 24: Scanning electron microscopy (SEM) of (PEG-MEM-PLGA) SANs at (a-b) scale 500 nm (c) showed Particle size, polydispersity index and zeta potential plot of (PEG-MEM-PLGA) SANs.....	86
Figure 25: (a) Biodegradation of (PEG-MEM-PLGA) SANs at pH 1.2, 5.7, 6.8 and 7.4 and blank during a four-week study. (b) Swelling index of (PEG-MEM-PLGA) SANs at pH 1.2, 5.7, 6.8 and 7.4.	88
Figure 26: In-vitro release profile of (a) (PEG-MEM-PLGA) SANs at pH 1.2, 5.7, 6.8 and 7.4 and Memantine HCL Tablets at pH 6.8 (b) A comparative drug release profile of MEMp, (MEM-PLGA) SANs, (PEG-MEM-PLGA) SANs and Admenta (Marketed tablet) at pH 6.8.	90
Figure 27: Drug release kinetic model of (PEG-MEM-PLGA) SANs.	91
Figure 28: Lineweaver–Burk plots for (a) AChE, (b) BUCHE and (c) β secretase inhibition over a range of substrate concentrations (10–50 μ M) and (75-450 μ m) from Brain homogenate samples in the presence of (0, 2.5, 5, 10, 20 μ M) and (0, 4, 8, 16 μ M) of memantine-loaded nanoscaffolds.	94
Figure 29: Lineweaver–Burk plots for (a) AChE, (b) BUCHE and (c) β secretase inhibition over a range of substrate concentrations (10–50 μ M) and (75-450 μ m) from Brain homogenate samples in the presence of (0, 2.5, 5, 10, 20 μ M) and (0, 4, 8, 16 μ M) of memantine-loaded nanoscaffolds.	96
Figure 30: Effect of 0, 2.5, 5, 10, 20 μ M (PEG-MEM-PLGA) SANs on AChE (fig. 8a and 8b) and BUCHE (fig 6c and 6d). Fig 6e and 6f shows the effect of (PEG-MEM-PLGA) SANs on β secretase activity in mice cortex and hippocampus. Product formed was (Acetylcholine) upon 60 min of incubation.....	97
Figure 31: Inhibition activity of 0, 2.5, 5, 10, and 20 μ M (PEG-MEM-PLGA) SANs on AChE, BUCHE, and β secretase activity in mice cortex and hippocampus. Each value represents mean \pm S.E.M. (n = 3). *p < 0.05.	98
Figure 32: Hemocompatibility assay of 0, 2, 4, 6, 8, 10 and 12 mg/ml (PEG-MEM-PLGA) SANs in mice blood. Each value represents mean \pm S.E.M. (n = 3). *p < 0.05. 20 μ l blood was added to saline water for negative control (0% hemolysis), whereas 20 μ l blood was added to the Triton X-100(1%v/v) for positive control (100% hemolysis).	100
Figure 33: Neurobehavioral effect in Y-maze test on % spontaneous alteration and total distance travelled in morris water maze test.....	101
Figure 34: (a) Y-maze parameter analysis of Time spent in Arm C, B, A and total distance travelled; and (b) Spontaneous alteration in behavior by animal groups; each value represents mean \pm S.E.M. (n = 3). *p < 0.05; (c-g) trajectories covered by (c) diseased control (DC), (d) MEMp (Standard), (e) (MEM-PLGA)SANs, (f) (PEG-MEM-PLGA)SANs and (g) (PEG-MEM-PLGA)SANs-BMSc treated group; (h) Morris water maze analysis of time spent in quadrants NW, NE, SW, SE and platform, total distance travelled, average speed, path efficiency.	105
Figure 35: Chromatogram of Memantine hydrochloride tablet (Admenta).	110
Figure 36: Reverse Phase-High Performance Liquid Chromatography (RP HPLC) Chromatogram of memantine on administration of (a) pure memantine drug (in serum) (b) PEGylated memantine loaded PLGA nanoscaffolds (in serum) (c) memantine drug (in brain tissue homogenates) (d) PEGylated memantine loaded PLGA nanoscaffolds (in brain tissue homogenates) (e) memantine loaded nanoscaffolds (in liver tissue homogenates) (f) memantine loaded nanoscaffolds (in kidney tissue homogenates).	112
Figure 37: (a) Plasma calibration curve of memantine (1–1000 μ g/ml) (b) Comparative Plasma drug concentration profile of (PEG-MEM-PLGA)SANs, (MEM-PLGA)SANs, MEMp and Admenta.	116
Figure 38: Concentration of Memantine released from (PEG-MEM-PLGA) SANs, (MEM-	

PLGA) SANs, MEMp and Admenta in brain, liver and kidney. **(g)** Comparative biodistribution pattern of drug from (PEG-MEM-PLGA) SANs in brain, liver and kidney; Each value represents mean \pm S.E.M. (n = 3). P value represents significance by showing *p < 0.05, **p<0.01, ***p<0.001 as compared to standard group (Memantine pure drug suspension 10mg/kg)..... 118

Figure 39: Estimation of Biochemical Parameters..... 120

Figure 40: Cross-section of brain taken from (a) control group (b) diseased mice (c) treated animals (with PLGA nanoscaffolds) 122

Figure 41: Cross-section of brain taken from Alzheimer’s disease induced mice and recovery of neurons and neuroregeneration after 1, 6 and 9 week of treatment after treatment with (PEG-MEM-PLGA) SANs. 123

Figure 42: Pathways of neurodegeneration in microglial cell, and release of pro-inflammatory cytokines in Alzheimer’s disease. 125

Figure 43: Expression of pro-inflammatory cytokines IL-1 β , IL-6, IL-10 and TNF- α in MEMp, Marketed, T1-(MEM-PLGA) SANs, T2-(PEG-MEM-PLGA) SANs and T3-(PEG-MEM-PLGA)-BMSc SANs in (a) serum, (b) cerebral tissue, (c) hepatic tissue and (d) renal tissues of treatment groups of scopolamine induced AD model. vs. control and disease control (untreated cells) group. Data has been represented as Mean \pm SEM, (n = 3). 127

Figure 44: Effect of MEMp, Marketed, (MEM-PLGA) SANs, (PEG-MEM-PLGA) SANs and (PEG-MEM-PLGA)-BMSc SANs on pro-inflammatory cytokines (a) IL-1 β (b) IL-6 (c) IL-10 and (d) TNF- α observed in serum, cerebral, hepatic and renal tissues of treatment groups of scopolamine induced AD model vs. control and disease control (untreated cells) group and Data are represented as Mean \pm SEM, (n = 3). 133

List of Tables

Table 1: Box Behnken design of PLGA nanoscaffolds.....	46
Table 2: Effect of pro-inflammatory cytokines on neurons and A β plaque	59
Table 3: Box-Behnken design table with the response value	67
Table 4: Response table determines delta value of (a) means, (b) S/N ratio and (c) Standard deviation	68
Table 5: Optimized batch characteristics with the value of correlation coefficient (adjusted and predicted).....	72
Table 6: Analysis of variance with degree of freedom (DF), an adjusted sum of square (Adj SS), Adjusted mean of square (Adj MS), F-value and P-value of the experimental model.....	72
Table 7: Optimized Memantine loaded nanoscaffolds with predicted and experimental responses with relative errors	77
Table 8: Accelerated stability study performed in two storage conditions.....	89
Table 9: Maximum inhibitory effect and IC ₅₀ value of (PEG-MEM-PLGA) SANs on AChE, BUCHE and β secretase	99
Table 10: Animal groups showing % spontaneous alteration in behavior	101
Table 11: Y-maze parameters analysis by using Any-Maze software	104
Table 12: Morris water maze (MWM) test parameters analysis by using Any-Maze software	107
Table 13: Pharmacokinetic Parameters of (PEG-MEM-PLGA) SANs, MEM-PLGA) SANs, MEMp, and Admenta	113
Table 14: Biodistribution study 30 min and 72 hours post administration of (PEG-MEM-PLGA) SANs, (MEM-PLGA) SANs, MEMp and Admenta	117
Table 15: Recovery of memantine in serum, brain, liver and kidney.....	119
Table 16: Biochemical parameters of Control, Diseased, MEMp, Admenta, (MEM-PLGA)SANs and (PEG-MEM-PLGA)SANs.....	121
Table 17: Estimated pro-inflammatory cytokines concentration in serum, cerebral, hepatic and renal tissue	128

